Compare CRSR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSR | CRVS |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2020 | 2016 |
| Metric | CRSR | CRVS |
|---|---|---|
| Price | $13.39 | $12.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $8.50 | ★ $30.17 |
| AVG Volume (30 Days) | ★ 1.1M | 809.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.37 | 48.04 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $1,472,480,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | $79.53 | ★ N/A |
| Revenue Growth | ★ 11.86 | N/A |
| 52 Week Low | $4.48 | $6.12 |
| 52 Week High | $14.98 | $26.95 |
| Indicator | CRSR | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the United States (U.S.), Americas (excluding U.S.) , Europe and the Middle East, and the Asia Pacific, of which maximum revenue is generated from United States (U.S.).
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.